Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function Clinical Trial

Official title:
A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function

Status Completed

Clinical Trial Summary

This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Impaired Hepatic Function

Clinical Trial Details

NCT number	NCT04823702
Study type	Interventional
Source	NGM Biopharmaceuticals, Inc
Contact
Status	Completed
Phase	Phase 1
Start date	April 1, 2021
Completion date	November 19, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04136444` - A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function	Phase 1
Completed	`NCT02135302` - A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects	Phase 1
Completed	`NCT02388620` - Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011	Phase 1
Completed	`NCT01764776` - Effect of Hepatic Impairment on LDE225..	Phase 1
Completed	`NCT01950481` - Effect of Hepatic Impairment on LDK378 Pharmacokinetics	Phase 1
Completed	`NCT00398424` - Evaluating Patients With Impaired Hepatic Function	Phase 1
Recruiting	`NCT05259085` - Study of ALXN2050 in Participants With Hepatic Impairment	Phase 1